CVS HEALTH CORP (CVS) Stock Analyst Ratings
USA - NYSE:CVS - US1266501006 - Common Stock
78.66 USD
+0.11 (+0.14%)
78.63 USD
-0.03 (-0.04%)
ChartMill assigns a Buy % Consensus number of 80% to CVS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 86.52. This target is 9.99% above the current price.
CVS was analyzed by 34 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about CVS.
In the previous month the buy percentage consensus was at a similar level.
CVS was analyzed by 34 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-03 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-30 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-30 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-30 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-24 | UBS | Maintains | Buy -> Buy |
| 2025-10-14 | Goldman Sachs | Initiate | Buy |
| 2025-10-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-09 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-09-05 | Bernstein | Maintains | Market Perform -> Market Perform |
| 2025-09-04 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-26 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-08-18 | UBS | Upgrade | Neutral -> Buy |
| 2025-08-14 | Baird | Upgrade | Neutral -> Outperform |
| 2025-08-01 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-01 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-22 | UBS | Maintains | Neutral -> Neutral |
| 2025-06-30 | Jefferies | Maintains | Buy -> Buy |
| 2025-06-02 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-12 | Truist Securities | Maintains | Buy -> Buy |
| 2025-05-06 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-05 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-02 | UBS | Maintains | Neutral -> Neutral |
| 2025-05-02 | Barclays | Maintains | Overweight -> Overweight |
| 2025-04-15 | Baird | Maintains | Neutral -> Neutral |
| 2025-04-11 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-09 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-03-21 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-18 | JP Morgan | Maintains | Overweight -> Overweight |
CVS HEALTH CORP / CVS FAQ
What is the price target for CVS stock?
34 analysts have analysed CVS and the average price target is 86.52 USD. This implies a price increase of 9.99% is expected in the next year compared to the current price of 78.66.
Can you provide the consensus rating for CVS HEALTH CORP stock?
The consensus rating for CVS HEALTH CORP (CVS) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.